<DOC>
	<DOCNO>NCT02547740</DOCNO>
	<brief_summary>Glaucoma lead cause irreversible blindness worldwide . This study aim test new method may allow early diagnosis glaucoma well way monitor get bad . There scientific evidence macula , central part retina , involve early stage glaucoma . Glaucomatous damage macula prevalent often miss use conventional clinical test . Relatively little known progression early glaucoma damage effect macula . This project investigate nature progressive damage macula propose new method improve accuracy detect clinically significant progression.The study evaluate nature damage macula 's structure OCT image eye function via visual field test .</brief_summary>
	<brief_title>Macular Damage Early Glaucoma Progression</brief_title>
	<detailed_description>There compel evidence glaucomatous damage macula occur even early stage disease . The macula comprise 30 % retinal ganglion cell information correspond 50 % visual cortex . However , glaucomatous damage macula often miss clinical practice . Some reason : 1. traditional glaucoma knowledge support glaucoma fundamentally peripheral disease ; 2. inherent limitation conventional clinical test detect damage macula ; 3. paucity large , prospective study describe nature glaucomatous damage macula . The investigator publish numerous paper past two year show macular damage prevalent among patient early glaucoma one employ appropriate tool assess , namely 10-2 visual field high-resolution optical coherence tomography ( OCT ) . This information come unique prospective cross- sectional database technique investigator develop produce objective metric structure function . Now investigator understand cross-sectional nature macular damage , proposal aim : 1. develop longitudinal database include patient early glaucoma healthy control , 2. test model explain progression macular damage , 3. apply new statistical method combine structural functional test could improve accuracy detect progression shorten length clinical trial . The main hypothesis incorporate 10-2 visual field test high-resolution OCT scan macula conventional repertoire technology use clinical practice , addition translate recently describe statistical method software use daily practice , enhance performance confidence detect glaucoma progression . In Aim 1 investigator plan follow healthy subject glaucoma patient regular interval 10-2 , 24-2 visual field , sweep source ( s ) OCT test define metric short- long-term test variability need differentiate true progression 'noise ' . To date , database combine technology . In Aim 2 investigator plan combine metric structure function longitudinal database use two method : spatial approach , ultimately produce joint structure-function index use 10-2 ssOCT data ; temporal approach , employ Bayesian statistic measure rate progression use trend analysis . By end study , contribution field : 1. make available unique pristine longitudinal database could use hypothesis test , 2. translate technique recently describe literature objective tool readily useful clinical practice , 3. mitigate burden progressive loss central vision glaucoma .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Glaucoma Group : glaucomatous optic neuropathy ( defined American Academy Ophthalmology Preferred Practice Pattern criterion ) late functional glaucomatous damage significant cataract previous ocular surgery ( aside uncomplicated cataract extraction intraocular lens ( IOL ) implantation and/or trabeculectomy ) diabetic retinopathy macular edema vein artery occlusion exudative agerelated macular degeneration geographic atrophy macular hole traction amblyopia uveitis nonopen angle glaucoma ( e.g . angle closure , traumatic , congenital glaucoma ) Healthy Group : best correct visual acuity equal well 20/40 normal biomicroscopy examination gonioscopically open angle Intraocular Pressure ( IOP ) low 22 mmHg normal reliable 242 102 SAP result evidence optic neuropathy evidence clinically significant metabolic disease ( e.g . diabetes hypotension )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>macula</keyword>
	<keyword>visual field</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>glaucoma progression</keyword>
	<keyword>retinal ganglion cell</keyword>
</DOC>